Antifungal drug resistance mechanisms in pathogenic fungi: From bench to bedside

Clinical Microbiology and Infection

Volumn 20, Issue 6, 2014, Pages 54-59

  Cuenca Estrella, M ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Aspergillus; Candida; Mutations; Mycosis; Tandem repeat

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN; PYRROLE; PYRROLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ASPERGILLUS; CANDIDA; CLINICAL PRACTICE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RELIABILITY; REVIEW; DRUG EFFECTS; FUNGUS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOSES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

EID: 84922271120     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12495     Document Type: Review

References (53)

1. Cuenca-Estrella M, Rodriguez-Tudela JL. The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro. Expert Rev Anti Infect Ther 2010; 8: 267-276.
2. Rodriguez-Tudela JL, Arendrup MC, Cuenca-Estrella M, Donnelly JP, Lass-Flörl C. EUCAST breakpoints for antifungals. Drug News Perspect 2010; 23: 93-97.
3. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 2012; 18: E246-E247.
4. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard-second edition. CLSI document M38-A2. Wayne, PA, USA: Clinical Laboratory Standards Institute, 2008.
5. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard-third edition. CLSI document M27-A3. Wayne, PA, USA: Clinical Laboratory Standards Institute, 2008.
6. Cuenca-Estrella M, Verweij PE, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18 (Suppl 7): 9-18.
7. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-447.
8. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-176.
9. Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70: 330-343.
10. Dannaoui E, Paugam A, Develoux M, et al. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories. Clin Microbiol Infect 2010; 16: 863-869.
11. Cuenca-Estrella M, Bassetti M, Lass-Flörl C, Racil Z, Richardson M, Rogers TR. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011; 66 (Suppl 1): i15-i24.
12. Perlin DS. Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis 2009; 22: 568-573.
13. Alastruey-Izquierdo A, Mellado E, Pelaez T, et al. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 2013; 57: 3380-3387.
14. Arendrup MC, Dzajic E, Jensen RH, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013; 19: e343-e353.
15. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-921.
16. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Rodriguez-Tudela JL. Detection of resistance to amphotericin B in Candida isolates by using Iso-Sensitest broth. Antimicrob Agents Chemother 2001; 45: 2070-2074.
17. Lass-Flörl C, Arendrup MC, Rodriguez-Tudela JL, Cuenca-Estrella M, Donnelly P, Hope W. EUCAST technical note on Amphotericin B. Clin Microbiol Infect 2011; 17: E27-E29.
18. Lass-Flörl C, Alastruey-Izquierdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL. In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009; 53: 794-795.
19. Balkis MM, Leidich SD, Mukherjee PK, Ghannoum MA. Mechanisms of fungal resistance: an overview. Drugs 2002; 62: 1025-1040.
20. Blum G, Perkhofer S, Haas H, et al. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother 2008; 52: 1553-1555.
21. Hull CM, Bader O, Parker JE, et al. Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrob Agents Chemother 2012; 56: 6417-6421.
22. Hull CM, Parker JE, Bader O, et al. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob Agents Chemother 2012; 56: 4223-4232.
23. Alcazar-Fuoli L, Mellado E, Garcia-Effron G, et al. Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids 2008; 73: 339-347.
24. Jeans AR, Howard SJ, Al-Nakeeb Z, et al. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. J Infect Dis 2012; 206: 442-452.
25. Baddley JW, Marr KA, Andes DR, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the transplant-associated infection surveillance network. J Clin Microbiol 2009; 47: 3271-3275.
26. Denning DW, Park S, Lass-Flörl C, et al. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52: 1123-1129.
27. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5: e219.
28. Snelders E, Camps SM, Karawajczyk A, et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS ONE 2012; 7: e31801.
29. Sanglard D, Ischer F, Calabrese D, Micheli M, Bille J. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist Updat 1998; 1: 255-265.
30. Sanglard D, Coste A, Ferrari S. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res 2009; 9: 1029-1050.
31. Vale-Silva L, Ischer F, Leibundgut-Landmann S, Sanglard D. Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells. Infect Immun 2013; 81: 1709-1720.
32. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2003; 47: 1120-1124.
33. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 2004; 48: 2747-2750.
34. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol 2001; 39: 2431-2438.
35. Snelders E, Karawajczyk A, Verhoeven RJ, et al. The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol 2011; 48: 1062-1070.
36. Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65: 2116-2118.
37. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-1076.
38. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51: 1897-1904.
39. van der Linden JW, Camps SM, Kampinga GA, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013; 57: 513-520.
40. Krishnan-Natesan S, Chandrasekar PH, Alangaden GJ, Manavathu EK. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus. Int J Antimicrob Agents 2008; 32: 519-524.
41. Natesan SK, Lamichchane AK, Swaminathan S, Wu W. Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus. Diagn Microbiol Infect Dis 2013; 76: 458-463.
42. Albarrag AM, Anderson MJ, Howard SJ, et al. Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob Agents Chemother 2011; 55: 5113-5121.
43. Bowyer P, Mosquera J, Anderson M, Birch M, Bromley M, Denning DW. Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus. FEMS Microbiol Lett 2012; 332: 10-19.
44. Yang YL, Lin CC, Chang TP, et al. Comparison of human and soil Candida tropicalis isolates with reduced susceptibility to fluconazole. PLoS ONE 2012; 7: e34609.
45. Camps SM, Dutilh BE, Arendrup MC, et al. Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS ONE 2012; 7: e50034.
46. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 2011; 49 (Suppl 1): S90-S95.
47. Rajendran R, Mowat E, McCulloch E, et al. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob Agents Chemother 2011; 55: 2092-2097.
48. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305-2312.
49. Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents 2010; 35: 211-218.
50. Arendrup MC, Rodriguez-Tudela JL, Park S, et al. Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother 2011; 55: 1580-1587.
51. Duran-Valle MT, Gago S, Gomez-Lopez A, et al. Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin. Antimicrob Agents Chemother 2012; 56: 3417-3419.
52. Jensen RH, Johansen HK, Arendrup MC. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother 2013; 57: 614-617.
53. Beyda ND, Lewis RE, Garey KW. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother 2012; 46: 1086-1096.